<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-three consecutive patients undergoing related-donor BMT for <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) were conditioned with a combination of <z:chebi fb="0" ids="28901">busulfan</z:chebi> (BU) and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CY) </plain></SENT>
<SENT sid="1" pm="."><plain>GVHD prophylaxis was with <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> (CSP)/<z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX) in 15 patients, CSP/<z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> (MP) in six patients, and CSP/MP/MTX in two patients </plain></SENT>
<SENT sid="2" pm="."><plain>The most frequent regimen-related toxicities were oral mucosal (87% of patients, 61% &gt; or = grade II) and hepatic (82% of patients, 43% &gt; or = grade II) </plain></SENT>
<SENT sid="3" pm="."><plain>The overall incidence of grade II-IV <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD was 48% with eight patients dying of <z:hpo ids='HP_0011009'>acute</z:hpo> or <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD </plain></SENT>
<SENT sid="4" pm="."><plain>There have been five relapses, with the cumulative risk of relapse being 35% (95% confidence interval [CI], 16%-66%) </plain></SENT>
<SENT sid="5" pm="."><plain>Eight patients remain alive and well (median follow-up 27 months, range 15-70 months), with an estimated 3-year event-free survival (EFS) of 35% (95% CI, 17%-54%) </plain></SENT>
<SENT sid="6" pm="."><plain>Univariate analysis of EFS by pretransplant variables indicated that only age &lt; or = 35 years correlated with a favorable outcome (p = 0.04) </plain></SENT>
<SENT sid="7" pm="."><plain>BUCY is an effective, well-tolerated alternative conditioning regimen for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients undergoing allogeneic BMT </plain></SENT>
</text></document>